SGLT2-inhibitors in type-2 diabetes: The remaining questions!
As the SGLT2-i therapy progressively carves out a forte in the management of diabetes, multiple equally significant questions justly occupy the medical mind. Aspects pertinent to the influence of this therapy on the renal pathophysiology, the prevention of cardiovascular disease, and considerations for their safe use, hold immense relevance to clinical practice. This review attempts to make an appropriate clinical interpretation of the existing evidence, to evolve a practical perspective on some of these yet unanswered aspects.